GLP-1 Drugs: Interaction Risks With Oral Medications

 GLP-1 receptor agonists (RAs) are increasingly used in the treatment of diabetes and obesity. Their mechanisms of action include delayed gastric emptying, inhibition of glucagon secretion, beneficial modulation of the intestinal microbiome, and direct effects on hypothalamic nuclei.

These medications provide benefits beyond glycemic control and weight reduction. However, they are associated with gastrointestinal adverse events, including nausea, vomiting, abdominal pain, diarrhea, constipation, bloating, belching, and flatulence. Additional concerns include hypoglycemia in individuals receiving concomitant antidiabetic therapy; cholelithiasis, particularly at higher doses and with prolonged use; rare pancreatitis; loss of muscle and bone mass; treatment discontinuation rates of 4%-8%; weight regain after discontinuation; and high cost. 

Long-term data on benefits and risks remain limited, particularly regarding loss of muscle and bone mass, fracture risk, and other adverse outcomes.

These are challenges that highlight the need for further research and for strategies that improve access, adherence, and safety with GLP-1 RAs.

However, an additional challenge warrants closer attention: potential drug interactions.

Drug Interactions 

Interactions related to metabolism or transport have limited clinical relevance. The most clinically relevant interactions are linked to delayed gastric emptying, which can affect the absorption of co-administered oral medications and increase the time required to reach maximum concentration.

Interactions with concomitant use of of GLP-1 RAs and these drugs include:

• Oral contraceptives: Tirzepatide demonstrated significant changes in oral contraceptive levels.
• Levothyroxine: Oral semaglutide showed significant changes in levothyroxine levels.
• Insulin and sulfonylureas: When these agents are used together with GLP-1 RAs, the risk for hypoglycemia increases, requiring dose reduction

• Dipeptidyl peptidase 4 inhibitors: These agents should be discontinued when initiating GLP-1 RA therapy because both act through GLP-1 signaling and their combined use has not been adequately studied.
• Dabigatran: Pharmacokinetic modeling suggests that concomitant use with GLP-1 RAs may increase dabigatran levels by 205%, resulting in a substantial increase in systemic levels of dabigatran. 

In contrast, when used concomitantly with GLP-1 RAs, no clinically relevant changes in pharmacokinetics were seen for warfarin, digoxin, lisinopril, metformin, atorvastatin, and acetaminophen, despite changes in maximum concentration (Cmax) and time to reach maximum concentration (Tmax).

Implications 

Evidence on these interactions remains limited. Given widespread use of GLP-1 RAs, greater attention is needed, particularly with medications that have a narrow therapeutic index or require specific peak concentrations to achieve efficacy, such as certain antibiotics. Potential consequences include failure of contraception, hypoglycemia, hemorrhage, or decreased efficacy in treatments for hypothyroidism and infections.

https://www.medscape.com/viewarticle/glp-1-drugs-interaction-risks-oral-medications-2026a1000eg8